These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

207 related articles for article (PubMed ID: 29118968)

  • 1. Combination of EZH2 inhibitor and BET inhibitor for treatment of diffuse intrinsic pontine glioma.
    Zhang Y; Dong W; Zhu J; Wang L; Wu X; Shan H
    Cell Biosci; 2017; 7():56. PubMed ID: 29118968
    [TBL] [Abstract][Full Text] [Related]  

  • 2. EZH2 is a potential therapeutic target for H3K27M-mutant pediatric gliomas.
    Mohammad F; Weissmann S; Leblanc B; Pandey DP; Højfeldt JW; Comet I; Zheng C; Johansen JV; Rapin N; Porse BT; Tvardovskiy A; Jensen ON; Olaciregui NG; Lavarino C; Suñol M; de Torres C; Mora J; Carcaboso AM; Helin K
    Nat Med; 2017 Apr; 23(4):483-492. PubMed ID: 28263309
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Therapeutic targeting of polycomb and BET bromodomain proteins in diffuse intrinsic pontine gliomas.
    Piunti A; Hashizume R; Morgan MA; Bartom ET; Horbinski CM; Marshall SA; Rendleman EJ; Ma Q; Takahashi YH; Woodfin AR; Misharin AV; Abshiru NA; Lulla RR; Saratsis AM; Kelleher NL; James CD; Shilatifard A
    Nat Med; 2017 Apr; 23(4):493-500. PubMed ID: 28263307
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Preclinical evaluation of convection-enhanced delivery of liposomal doxorubicin to treat pediatric diffuse intrinsic pontine glioma and thalamic high-grade glioma.
    Sewing ACP; Lagerweij T; van Vuurden DG; Meel MH; Veringa SJE; Carcaboso AM; Gaillard PJ; Peter Vandertop W; Wesseling P; Noske D; Kaspers GJL; Hulleman E
    J Neurosurg Pediatr; 2017 May; 19(5):518-530. PubMed ID: 28291423
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Convection-Enhanced Delivery of Enhancer of Zeste Homolog-2 (EZH2) Inhibitor for the Treatment of Diffuse Intrinsic Pontine Glioma.
    Sasaki T; Katagi H; Goldman S; Becher OJ; Hashizume R
    Neurosurgery; 2020 Nov; 87(6):E680-E688. PubMed ID: 32674144
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Progress in diffuse intrinsic pontine glioma: advocating for stereotactic biopsy in the standard of care.
    Williams JR; Young CC; Vitanza NA; McGrath M; Feroze AH; Browd SR; Hauptman JS
    Neurosurg Focus; 2020 Jan; 48(1):E4. PubMed ID: 31896081
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Polo-like Kinase 1 as a potential therapeutic target in Diffuse Intrinsic Pontine Glioma.
    Amani V; Prince EW; Alimova I; Balakrishnan I; Birks D; Donson AM; Harris P; Levy JM; Handler M; Foreman NK; Venkataraman S; Vibhakar R
    BMC Cancer; 2016 Aug; 16():647. PubMed ID: 27538997
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Therapeutic HDAC inhibition in hypermutant diffuse intrinsic pontine glioma.
    Noll A; Myers C; Biery MC; Meechan M; Tahiri S; Rajendran A; Berens ME; Paine D; Byron S; Zhang J; Winter C; Pakiam F; Leary SES; Cole BL; Jackson ER; Dun MD; Foster JB; Evans MK; Pattwell SS; Olson JM; Vitanza NA
    Neoplasia; 2023 Sep; 43():100921. PubMed ID: 37603953
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Inhibition of microglial EZH2 leads to anti-tumoral effects in pediatric diffuse midline gliomas.
    Keane L; Cheray M; Saidi D; Kirby C; Friess L; Gonzalez-Rodriguez P; Gerdes ME; Grabert K; McColl BW; Joseph B
    Neurooncol Adv; 2021; 3(1):vdab096. PubMed ID: 34485907
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Potent preclinical sensitivity to imipridone-based combination therapies in oncohistone H3K27M-mutant diffuse intrinsic pontine glioma is associated with induction of the integrated stress response, TRAIL death receptor DR5, reduced ClpX and apoptosis.
    Borsuk R; Zhou L; Chang WI; Zhang Y; Sharma A; Prabhu VV; Tapinos N; Lulla RR; El-Deiry WS
    Am J Cancer Res; 2021; 11(9):4607-4623. PubMed ID: 34659909
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Current Murine Models and New Developments in H3K27M Diffuse Midline Gliomas.
    Welby JP; Kaptzan T; Wohl A; Peterson TE; Raghunathan A; Brown DA; Gupta SK; Zhang L; Daniels DJ
    Front Oncol; 2019; 9():92. PubMed ID: 30873381
    [TBL] [Abstract][Full Text] [Related]  

  • 12. No Significant Cytotoxic Effect of the EZH2 Inhibitor Tazemetostat (EPZ-6438) on Pediatric Glioma Cells with Wildtype Histone 3 or Mutated Histone 3.3.
    Wiese M; Schill F; Sturm D; Pfister S; Hulleman E; Johnsen SA; Kramm CM
    Klin Padiatr; 2016 Apr; 228(3):113-7. PubMed ID: 27135271
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Medulloblastoma therapy generates risk of a poorly-prognostic H3 wild-type subgroup of diffuse intrinsic pontine glioma: a report from the International DIPG Registry.
    Gits HC; Anderson M; Stallard S; Pratt D; Zon B; Howell C; Kumar-Sinha C; Vats P; Kasaian K; Polan D; Matuszak M; Spratt DE; Leonard M; Qin T; Zhao L; Leach J; Chaney B; Escorza NY; Hendershot J; Jones B; Fuller C; Leary S; Bartels U; Bouffet E; Yock TI; Robertson P; Mody R; Venneti S; Chinnaiyan AM; Fouladi M; Gottardo NG; Koschmann C
    Acta Neuropathol Commun; 2018 Jul; 6(1):67. PubMed ID: 30049282
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Emerging Advances in Combinatorial Treatments of Epigenetically Altered Pediatric High-Grade H3K27M Gliomas.
    Leszczynska KB; Jayaprakash C; Kaminska B; Mieczkowski J
    Front Genet; 2021; 12():742561. PubMed ID: 34646308
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Potent anti-tumor efficacy of palbociclib in treatment-naïve H3.3K27M-mutant diffuse intrinsic pontine glioma.
    Sun Y; Sun Y; Yan K; Li Z; Xu C; Geng Y; Pan C; Chen X; Zhang L; Xi Q
    EBioMedicine; 2019 May; 43():171-179. PubMed ID: 31060906
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Inhibition of mutant PPM1D enhances DNA damage response and growth suppressive effects of ionizing radiation in diffuse intrinsic pontine glioma.
    Akamandisa MP; Nie K; Nahta R; Hambardzumyan D; Castellino RC
    Neuro Oncol; 2019 Jun; 21(6):786-799. PubMed ID: 30852603
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Combined treatment with CBP and BET inhibitors reverses inadvertent activation of detrimental super enhancer programs in DIPG cells.
    Wiese M; Hamdan FH; Kubiak K; Diederichs C; Gielen GH; Nussbaumer G; Carcaboso AM; Hulleman E; Johnsen SA; Kramm CM
    Cell Death Dis; 2020 Aug; 11(8):673. PubMed ID: 32826850
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Targeting Mutant PPM1D Sensitizes Diffuse Intrinsic Pontine Glioma Cells to the PARP Inhibitor Olaparib.
    Wang Z; Xu C; Diplas BH; Moure CJ; Chen CJ; Chen LH; Du C; Zhu H; Greer PK; Zhang L; He Y; Waitkus MS; Yan H
    Mol Cancer Res; 2020 Jul; 18(7):968-980. PubMed ID: 32229503
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Combined Targeting of Mutant p53 and Jumonji Family Histone Demethylase Augments Therapeutic Efficacy of Radiation in H3K27M DIPG.
    Nikolaev A; Fiveash JB; Yang ES
    Int J Mol Sci; 2020 Jan; 21(2):. PubMed ID: 31940975
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Targeting Wee1 for the treatment of pediatric high-grade gliomas.
    Mueller S; Hashizume R; Yang X; Kolkowitz I; Olow AK; Phillips J; Smirnov I; Tom MW; Prados MD; James CD; Berger MS; Gupta N; Haas-Kogan DA
    Neuro Oncol; 2014 Mar; 16(3):352-60. PubMed ID: 24305702
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.